PMID- 24252442
OWN - NLM
STAT- MEDLINE
DCOM- 20140827
LR  - 20140103
IS  - 1873-5177 (Electronic)
IS  - 0091-3057 (Linking)
VI  - 116
DP  - 2014 Jan
TI  - A 3-lever discrimination procedure reveals differences in the subjective effects 
      of low and high doses of MDMA.
PG  - 9-15
LID - S0091-3057(13)00303-1 [pii]
LID - 10.1016/j.pbb.2013.11.011 [doi]
AB  - Drug discrimination studies have suggested that the subjective effects of low 
      doses of (+/-)3,4-methylenedioxymethamphetamine (MDMA) are readily differentiated 
      from those of d-amphetamine (AMPH) and that the discriminative stimulus 
      properties are mediated by serotonergic and dopaminergic mechanisms, 
      respectively. Previous studies, however, have primarily examined responses to 
      doses that do not produce substantial increases in extracellular dopamine. The 
      present study determined whether doses of MDMA that produce increases in synaptic 
      dopamine would also produce subjective effects that were more like AMPH and were 
      sensitive to pharmacological manipulation of D1-like receptors. A three-lever 
      drug discrimination paradigm was used. Rats were trained to respond on different 
      levers following saline, AMPH (0.5mg/kg, IP) or MDMA (1.5mg/kg, IP) injections. 
      Generalization curves were generated for a range of different doses of both drugs 
      and the effect of the D1-like antagonist, SCH23390 on the discriminative stimulus 
      effects of different doses of MDMA was determined. Rats accurately discriminated 
      MDMA, AMPH and saline. Low doses of MDMA produced almost exclusive responding on 
      the MDMA lever but at doses of 3.0mg/kg MDMA or higher, responding shifted to the 
      AMPH lever. The AMPH response produced by higher doses of MDMA was attenuated by 
      pretreatment with SCH23390. The data suggest that low doses and higher doses of 
      MDMA produce distinct discriminative stimuli. The shift to AMPH-like responding 
      following administration of higher doses of MDMA, and the decrease in this 
      response following administration of SCH23390 suggests a dopaminergic component 
      to the subjective experience of MDMA at higher doses.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Harper, David N
AU  - Harper DN
AD  - Victoria University of Wellington, New Zealand. Electronic address: 
      david.harper@vuw.ac.nz.
FAU - Langen, Anna-Lena
AU  - Langen AL
AD  - Victoria University of Wellington, New Zealand.
FAU - Schenk, Susan
AU  - Schenk S
AD  - Victoria University of Wellington, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20131116
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/toxicity
MH  - Rats
OTO - NOTNLM
OT  - Dopamine
OT  - Drug discrimination
OT  - MDMA
OT  - SCH23390
OT  - d-Amphetamine
EDAT- 2013/11/21 06:00
MHDA- 2014/08/29 06:00
CRDT- 2013/11/21 06:00
PHST- 2013/04/22 00:00 [received]
PHST- 2013/11/01 00:00 [revised]
PHST- 2013/11/08 00:00 [accepted]
PHST- 2013/11/21 06:00 [entrez]
PHST- 2013/11/21 06:00 [pubmed]
PHST- 2014/08/29 06:00 [medline]
AID - S0091-3057(13)00303-1 [pii]
AID - 10.1016/j.pbb.2013.11.011 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2014 Jan;116:9-15. doi: 10.1016/j.pbb.2013.11.011. Epub 
      2013 Nov 16.